药物对比
Canagliflozin vs Saxagliptin
Canagliflozin（Invokana）与Saxagliptin（Onglyza）：SGLT2抑制剂与DPP-4抑制剂治疗2型糖尿病。机制、疗效、安全性及心血管保护方面的差异。
此页面暂无可用的对比维度。
临床背景
This comparison arises when choosing between an SGLT2 inhibitor and a DPP-4 inhibitor as add-on oral therapy for type 2 diabetes.
结论
Neither is better overall because they target type 2 diabetes via distinct mechanisms with unique benefits and risks.
全部药物对比